Rockwell Inks $3.7M Investor Deal Over Dialysis Drug Claims
Investors have reached a $3.7 million deal with Rockwell Medical to settle claims that the biopharmaceutical company misled them into believing its dialysis drug, Triferic, was poised to dominate the market....To view the full article, register now.
Already a subscriber? Click here to view full article